Our Team
Meet Our Team
Jonathan is a co-founder and President & CEO of Hopewell Pharma Ventures. He has a Ph.D degree from Aston University, U.K. and 30 years of experience in the pharmaceutical industry. He has a broad range of expertise in drug delivery systems, specialty and generic products, contract manufacturing, product development and commercialization, business development and licensing.
Before starting Hopewell, Jonathan was the Chief Business Officer at Amerigen Pharmaceuticals, a generic pharmaceuticals company operating in the U.S. and China markets. He was in charge of business/corporate development and sales, product selection and patent litigation. He launched 12 U.S. generic products at Amerigen, including 9 in 2018-2019, some of which were the first generics of their kind. He sold to all the major buying groups and government channels.
Jonathan also worked as the Vice President of Product Ventures at Catalent Pharma Solutions, and was a member of the Catalent Executive Leadership Team. He spent over 15 years at Cardinal Health in various roles based in the U.K., Switzerland and the U.S. He was instrumental in bringing several important first generics to the U.S. market.
Chief Executive Officer
Wenbin is a co-founder and EVP and CSO of Hopewell Pharma Ventures. She has a Ph.D degree from Johns Hopkins University, U.S. and more than 30 years of experience in the pharmaceutical industry. She has a deep knowledge of R&D and manufacturing, including innovative products, drug delivery systems and generic products, across a wide range of dosage forms (oral, topical, inhalation and sterile products).
Before joining Hopewell, Wenbin was the Senior Vice President of Product Development at Amerigen Pharmaceuticals, a generic pharmaceuticals company operating in the U.S. and China markets. She was responsible for all aspects of pharmaceutical product development, including formulation, analytical, clinical, regulatory affairs and project management. She developed 24 generic products at Amerigen, including first-to-file PIV ANDAs and several first generics.
Wenbin also worked as the Vice President of Product Development at Catalent Pharma Solutions and was a member of the Catalent Senior Leadership Team. She managed the pharmaceutical development of numerous important branded and generic products. She also had over 14 years of R&D experience at Cardinal Health, Guilford Pharmaceuticals and Alkermes.
Chief Scientific Officer
Jayesh is a co-founder and Chief Business Officer of Hopewell Pharma Ventures. He has over 20 years of experience in the pharmaceutical industry, spanning both specialty and generic products. He has a strong track record of portfolio management, strategy, commercialization, M&A and licensing. He holds an MBA degree with dual specialization in Finance and Marketing from Rutgers University, U.S.
Before co-founding Hopewell, Jayesh was the Vice President of Business Development and Portfolio Management at Amerigen Pharmaceuticals, where he was responsible for product selection, alliance management, business development and supply chain. He also served as a senior leader at Ranbaxy USA (now Sun), where he led global strategy, corporate development and business development activities.
Jayesh has successfully developed and executed go-to-market plans and strategies for products generating over $150 million in gross margin. He has in-licensed, acquired, partnered and launched more than 70 products across different dosage forms.
Chief Business Officer
Brijesh is the VP Research & Development of Hopewell Pharma Ventures. He has a Ph.D degree from North Gujarat University, India and 22 years of experience in the pharmaceutical industry. He has a strong focus on generic product development, scale up and technology transfer.
Before joining Hopewell, Brijesh was the Senior Director of Product Development at Amerigen Pharmaceuticals, a generic pharmaceuticals company operating in the U.S. and China markets. He was responsible for formulation development of Amerigen’s generic products. He also played a key role in developing and commercializing multiple first-time generics in various markets, such as Rabeprazole tablets (Rabeloc™-India), Valacyclovir Tablets (Canada), Quinapril and Quinapril-HCTZ tablets (Canada), Tizanidine Capsules (USA) and Eplerenon Tablets (USA), Penicillamine Capsules (USA) and Miglustat Capsules (USA).
Brijesh also worked as a product development and commercial manufacture leader for an oncology product (Zejula®) at GlaxoSmithKline in 2020-2021. He has also worked as a formulation and technology transfer expert at various pharmaceutical companies in Canada (Apotex Inc, Patheon Inc and Pharmascience) and in India (Cadila Pharmaceuticals, Claris Lifescience).
Vice President, R&D
Balaji is the VP Regulatory Affairs of Hopewell Pharma Ventures. He has 12 years of experience in the pharmaceutical industry, covering U.S. and Europe new drugs and U.S. generic products. He has a M.S. degree from Northeastern University, U.S. and a B. Pharm. degree from Osmania University, India.
Before joining Hopewell, Balaji was the Director of Global Regulatory Affairs at Otsuka Pharmaceuticals, where he was responsible for CMC and clinical regulatory strategy for products under development in the U.S. and Europe markets. He also served as the Site Head of Regulatory Affairs at Par Pharmaceuticals, Irvine, CA, where he was in charge of Regulatory strategy and CMC for products from development to commercialization.
Balaji has provided regulatory support by developing, driving and implementing regulatory strategies for new products and life cycle management of marketed products. He has served as an interface with FDA and demonstrated leadership in regulatory aspects within and across functions to achieve business objectives. He has also worked as a regulatory lead at various pharmaceutical companies, such as Perrigo, Wockhardt and Cipla.
Vice President, Regulatory Affairs